Skip to main content

International Psoriasis Council

Advancing Knowledge. Improving Care.

Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque Psoriasis

Psoriasis News BMS graphic

Bristol Myers Squibb (NYSE:BMY) announced this week that the European Commission has approved Sotyktu (deucravacitinib), a first-in-class, selective tyrosine kinase 2 (TYK2) inhibitor, for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy, representing a new way of treating this chronic immune-mediated disease. The approval was based on results from the Phase 3 POETYK PSO-1 and POETYK PSO-2 clinical trials, which demonstrated a consistent safety profile in patients through three years of continuous treatment.

Learn more about Sotyktu – Summary of Product Characteristics. 

bristol myers squibb logo

Categories

Recent Posts

Highlights from the 2026 European Academy of Dermatology and Venereology (EADV) Congress: Personalized Medicine, Therapeutic Advances, and Late-Breaking Research

What Comes Next in Psoriasis Treatment: A Look at the Current Pipeline

When Cancer and Psoriasis Coexist: New IPC Guidance Puts Clarity Where It Is Needed Most

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.

What's New

Psoriasis: An Expert Global Perspective Is Now Available for Pre-Order

IPC Board Member and Treasurer Joel Gelfand, MD, MSCE, is the editor of a new textbook, Psoriasis: An Expert Global Perspective, now available for preorder from Elsevier. He worked with associate editors IPC President Bruce Strober, MD, PhD; IPC Vice President/President-Elect Claudia de la Cruz, MD; and IPC Chief Medical Officer Peter van de Kerkhof, MD, PhD. Nearly 50 authors from 20 countries contributed 30 chapters covering psoriasis from its earliest descriptions through genetics, immunology, and current therapies, with clinical images of psoriasis across diverse skin tones. All royalties support IPC.

PRE-ORDER YOUR COPY

Thursday, September 10, 2026

New Video Resource: Early Diagnosis and Treatment of Psoriatic Arthritis (PsA)

In this video, IPC Councilor Rodrigo Garcia Salinas, MD, a rheumatologist from Argentina, explains how to recognize psoriatic arthritis early, including why joint pain, how long a patient has had psoriasis, and family history can matter more than skin severity alone. He also reviews how imaging helps catch early disease and how to choose treatment based on each patient’s joint, spine, and skin involvement.

WATCH NOW

Friday, September 25, 2026

Take Ten Video: Bridging Psoriasis and Metabolic Comorbidities

IPC President Bruce Strober reviews the link between psoriasis and metabolic disease, drawing on findings from IPC’s recent paper in the Journal of the American Academy of Dermatology (JAAD). He translates this growing body of evidence into five concrete priorities from the 2025 IPC Think Tank for improving cardiometabolic screening and care.

WATCH NOW

Wednesday, September 9, 2026